Agenus Inc. — Q1 2020 Form 10-Q Summary
Business context and reporting period
Agenus is a clinical-stage immuno-oncology company developing antibody, vaccine and cell-therapy programs. This unaudited quarterly report covers the three months ended March 31, 2020; comparative results are for Q1 2019. The company had no products approved for commercial sale in the United States and no product-sales revenue.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 / prior date |
|---|---|---|
| Total revenue | $15.1 million | $79.9 million |
| Research and development revenue | $1.9 million | $70.9 million |
| Research and development expense | $36.4 million | $40.1 million |
| General and administrative expense | $10.6 million | $10.8 million |
| Operating loss (income) | $(27.5) million | $26.2 million |
| Net loss (income) | $(45.3) million | $17.4 million |
| Net loss attributable to common stockholders; basic and diluted EPS | $(44.7) million; $(0.31) | $18.5 million; $0.14 basic, $0.12 diluted |
| Cash and cash equivalents | $92.3 million | $61.8 million at Dec. 31, 2019 |
| Operating cash flow | $(34.5) million | $76.6 million |
| Debt | $13.6 million principal; $13.2 million carrying value | $14.1 million principal at Dec. 31, 2019 |
Q1 2020 revenue included $13.2 million of non-cash royalty revenue associated with royalties sold to Healthcare Royalty Partners (HCR). Interest expense was $14.0 million, including substantial non-cash interest related to that transaction. No operating margin was reported; the company recorded an operating loss. At March 31, current assets were $102.8 million and current liabilities were $127.3 million. Stockholders’ deficit was $202.5 million, and accumulated deficit was $1.33 billion.
Material changes versus the prior comparable period
- Revenue fell by $64.8 million year over year, principally because Q1 2019 included a $65.5 million Gilead license-fee recognition; Q1 2020 collaboration revenue was mainly deferred-revenue recognition.
- Results moved from operating income and net income in Q1 2019 to operating and net losses in Q1 2020. Lower R&D expense was partly offset by higher interest expense and a $2.7 million loss on modification of debt.
- Operating cash flow changed from $76.6 million provided to $34.5 million used. The 2019 inflow benefited from a $56.6 million increase in deferred revenue.
- Agenus raised $65.1 million net through at-the-market (ATM) stock sales in Q1, issuing approximately 24.7 million shares. Common shares issued increased to 163.3 million from 137.8 million at year-end.
- In February, the company extended $13.5 million of subordinated notes’ maturity to February 2023, repaid $0.5 million, and issued new and extended warrants. It recorded the $2.7 million debt-modification loss.
Outlook, management commentary, risks and unusual items
- Liquidity and going concern: Management said Q1-end cash plus financing completed in Q2 was expected to fund requirements through Q4 2020. The filing disclosed substantial doubt about the company’s ability to continue as a going concern for one year after filing, absent additional financing or transactions. Management contemplated further spending cuts if additional resources were not secured by the end of Q2.
- Subsequent financing: From April 1 to May 7, Agenus raised $15.9 million net through ATM sales, issuing approximately 6.1 million shares. In May, it obtained approximately $6.2 million in Paycheck Protection Program loans at 1% interest, with potential forgiveness subject to SBA approval and program requirements.
- COVID-19: The company reported a March workforce reduction, slowed non-priority programs, and repurposed some R&D toward potential COVID-19 treatments. The CEO elected to receive the remainder of his 2020 base salary in stock. Management said approximately $45 million of partner milestone payments expected later in 2020 were delayed and unlikely to arrive that year, affecting runway.
- Development plans: Agenus expected to file two BLAs for balstilimab monotherapy and balstilimab/zalifrelimab combination therapy in second-line cervical cancer in the second half of 2020, aiming for potential commercialization in 2021. The filing cautions that timelines depend on clinical results, FDA review, and COVID-related trial disruption; the company did not expect to be profitable in 2021.
- Clinical data: The filing cited interim overall response rates of approximately 11.9% for balstilimab monotherapy and 26.5% for the combination. It warns that interim results may change and may not support approval. The company said a confirmatory trial needed to be substantially underway at BLA submission for the planned accelerated-approval pathway.
- Royalty financing: Agenus had sold HCR 100% of its rights to future GSK QS-21 royalties. Q1 royalty revenue was non-cash to Agenus, while the related liability generated non-cash interest expense; the estimated effective annual interest rate increased to 26.2%.
- Other risks: The business depends on successful clinical development, regulatory approval, commercial launch and partner performance. Additional risks include financing and dilution, trial delays or failure, manufacturing and supply constraints, competition, and the ability to secure partnerships. The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether new financing, partnerships or licensing transactions extend the cash runway beyond Q4 2020, and whether the going-concern uncertainty changes.
- Timing and receipt of the delayed partner milestones, and any further effects of COVID-19 on trials, operations or partner programs.
- Final cervical-cancer trial results, confirmatory-trial progress, FDA acceptance of the BLA pathway and actual filing or approval timelines.
- ATM share issuance, remaining sales capacity, potential dilution, and the terms and forgiveness status of the $6.2 million PPP loans.
- HCR royalty-liability accretion and interest expense, along with future royalty and milestone estimates.